Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Alzheimer's Disease

Trial Information

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Official Title: A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients

Summary

Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.

Phase: Phase 1

Sponsor: Chugai Pharmaceutical

Overall Contacts:

Akira Chiba

Locations (5)

Country State City Zip Facility and Contact
Japan Kansai Kansai region
Akira Chiba
clinical-trials@chugai-pharm.co.jp
Japan Kanto Kanto region,
Akira Chiba
clinical-trials@chugai-pharm.co.jp
Japan Kyushu Kyushu region
Akira Chiba
clinical-trials@chugai-pharm.co.jp
Japan Toakai Tokai region
Akira Chiba
clinical-trials@chugai-pharm.co.jp
Japan Tohoku Tohoku region
Akira Chiba
clinical-trials@chugai-pharm.co.jp

NCT ID:NCT01656525

Date Last Changed: October 1, 2012